Trial Profile
An open label, randomised healthy volunteer study to assess the single dose safety and pharmacokinetics of three modified release dosage forms of firategrast
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors GSK
- 25 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01424462).
- 10 Aug 2010 New trial record.